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ABSTRACT 
 
Introduction: Deranged immunologic capability has been widely implicated in diabetic 
subjects. It is not well documented if dysfunctional humoral antibodies that occur in DM 
leads to susceptibility to infections as a result of poor glycaemic control  or a reaction that 
occurs when the infection has already set in. We sought to evaluate the pattern of humoral 
immune response in Nigerians with Diabetic mellitus with and without complications and 
its association with glycaemic control indices. Methods: This was a cross sectional 
analytical study conducted on 150 people with type 2 DM between the ages of 38 and 80 
years and 75 age and sex matched healthy controls. Presence of co morbidities and 
complications was sought for in the subjects. DM subjects were subdivided into early onset 
(less than five years duration) and long standing (greater than five years duration). 
Glycaemic control was assessed using fasting plasma glucose, fructosamine and 
glycosylated haemoglobin. Plasma immunoglobulins A, G, and M were estimated using 
elisa method. Results: The mean levels of all the studied immunoglobulins were 
comparable in DM and healthy controls save for immunoglobulin M which was significantly 
lower in DM. A significantly inverse association was observed between immunoglobulin G 
with fructosamine (r = - 0.356, p = 0.030) and glycosylated haemoglobin (r = -0.352, p = 
0.026). Immunoglobulin M was negatively associated with systolic blood pressure (r = - 
0.269, p = 0.034) and diastolic blood pressure (r = - 0.257, p = 0.044). Conclusion: Plasma 
levels of Immunoglobulin M are lower in subjects with DM than in people without DM. 
Plasma Immunoglobulin G and M levels are significantly and inversely associated with 
glycaemic control indices and blood pressures respectively in DM subjects. 
KEYWORDS: Diabetes mellitus, Immunoglobulins, Humoral immune response Glycaemic 
indices. 
 
INTRODUCTION 
Diabetes mellitus (DM) is a chronic metabolic disorder that is 
associated with considerable morbidity and mortality and 
people with diabetes have been shown to have higher 
mortality rates than people without diabetes[1]. Diabetic 
subjects are prone to macro and micro vascular 
complications.  These complications vary with different 
status, age at diagnosis, duration of illness, presence of organ 
complications, glycosylated haemoglobin, complement 
components and immunoglobulin levels [2]. Glycation is 
thought to contribute to the development of chronic vascular 
complications of diabetes. The glycation of nucleic acids 
causes DNA mutations and could alter its capacity for 
replication and transcription.  Non-enzymatic glycosylation of 
proteins is a gradual chemical process and one of the 
important cascades in the pathogenesis of diabetic 
complications and age accelerating disease.  A previous study 
has shown that glycation are found to be increased in 
immunoglobulin G (IgG) in diabetics [3]. The increased non 
enzymatic IgG-linked advanced glycation end product 
reduces defense mechanism of immunoglobulins. Glycation 
of immunoglobulin G (IgG) is of major value due to its 
possible influence on the dependency of other 
immunoglobulins and overall immunocompetence.  
The immune system has macrophages with special receptors 
for advanced glycation end products [4], which is impaired. 
With respect to the biological activity of immunoglobulin G 
(IgG) in diabetics; studies have also shown that certain 
functional properties of the fragment crystallisable (FC) 
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region of IgG are impaired. These include alteration in the 
binding of proteins and fixation of complement to the FC 
fragment, which probably contributes to the increased 
susceptibility to infections [5] in these subjects. The increased 
incidence of infections in patients with diabetes mellitus 
(DM) is well documented in literature and some of these 
infections are also more likely to have a complicated course 
[6], [7]. In a previous study by Derensinski, diabetic ketoacidosis 
was complicated by an infection in 75% of the cases. Possible 
causes include defects in immunity, increased adherence of 
microorganisms to diabetic cells, the presence of micro- and 
macroangiopathy or neuropathy.  It is interesting to note 
however, that dysfunctional humoral response reported in a 
previous study was associated with an unexplained increased 
levels of immunoglobulin A (IgA) in diabetic subjects that do 
not have any history of infection.[8] It is thus likely that these 
subjects may have subclinical infections especially those 
affecting   urinary and intestinal tract or that the elevated IgA 
levels are secondary to metabolic disturbance of diabetes.  
Humoral immunity is a complex reaction that involves the 
interdependent of complements, cytokines and 
immunoglobulins.  Whilst alterations of low complement 
factor 4, decreased cytokine responses after stimulation have 
been described in diabetic patients [9], the pattern of 
expression of the immunoglobulins  involved in humoral 
immune response have not been extensively studied.  It is 
plausible that dysfunctional humoral antibodies that occurs 
in DM leads to susceptibility to infections as a result of poor 
glycaemic control  or a reaction that occurs when the 
infection has already set in. The objective of this study 
therefore was to evaluate the pattern of humoral immune 
response in Nigerians with Diabetic mellitus and its 
association with glycaemic control indices.  
MATERIAL & METHODOLOGY  
Study design: This was a analytical cross sectional study 
carried over a period of 4 months from May 2015 to 
September 2015.  
Study population: The study population consisted of subjects 
with DM who were receiving care at the Diabetes Unit of 
Randle General Hospital, Lagos, and an urban hospital in 
Nigeria.  
Ethical approval: Informed consent was obtained from the 
study subjects and Ethical approval was given by the Ethics 
Committee of the hospital.  
Inclusion criteria: The study population included150 subjects 
with type 2 DM aged between 38 and 80 years. A total 
number of 75 sex and aged matched individuals served as 
healthy controls.  
Exclusion criteria: It included the following; those requiring 
haemodialysis, people ill enough to warrant hospitalization, 
pregnant women, persons who met inclusion criteria but did 
not give consent for the study.  
Methodology: Interview administered questionnaire were 
used to obtain medical history and to record clinical indices. 
Blood pressure (BP in mm/Hg) of all the subjects was 
measured on the left arm using Accuson mercury 
sphygmanometer. An appropriate sized cuff was placed 
about 2.5 cm above the antecubital fossa with participants 
sitting, after resting for at least ten minutes. 6.0ml of venous 
blood samples were collected from each subject in a sitting 
position after an overnight fast (10 – 24 hours). Plasma 
samples were collected after centrifugation and analyzed. 
Laboratory analyses:  The DM free status of the controls was 
ascertained by having them subjected to glycosylated 
haemoglobin and fasting plasma glucose tests. They were 
deemed as not having DM if their fasting plasma glucose and 
glycosylated haemoglobin were less than 100mg % and 5.7% 
[10] respectively. Short term, medium term and long term 
defined as glycosylated haemoglobin levels ≤ 7% [11]. The 
controls and the subjects all had biochemical tests done and 
these included plasma immunoglobulins A, G, and M.  
Glycosylated haemoglobin (HbA1c) was estimated using 
chromatographic – spectrophotometric ion exchange method 
using Biosystems kit, Spain. The name and model of the 
spectrophotometer used was SSRFI and BSA 3000. 
Fructosamine was estimated spectrophotometrically, using a 
kit adopted by Fortress, UK.  Fasting plasma glucose was 
estimated using glucose oxidase method. The 
immunoglobulins were measured by enzyme linked 
immunosorbent assay (Elisa) technique using commercial test 
kits of WKEA (China) for IgG and IgA  and  AccuDiag (USA)  for 
IgM respectively.  The absorbances were read with a micro 
plate reader (stat fax, USA, model no 2100).  
STATISTICAL ANALYSIS 
The statistical package used for the analysis was SPSS version 
15. Quantitative variables were compared with independent 
student t test. The comparison within and among groups 
were done using one way analysis of variance (ANOVA). 
Correlations were explored with Pearson’ correlation 
coefficient. Standard multiple regression analysis was used to 
predict outcomes. Quantitative data are expressed as mean ± 
standard deviation and mean ± standard error of mean. 
Probability values of less than 0.05 were considered to be 
statistically significant. 
RESULTS 
The mean age, standard deviation (SD) and age range of the 
study subjects were 59.9 (10.2) years and 38 – 80 years 
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glycaemic control were assessed using fasting glucose, 
fructosamine and glycosylated haemoglobin respectively. 
Short - term good glycaemic control was defined as fasting 
plasma glucose levels ≤ 110mg%. Medium - term good 
glycaemic control was defined as fructosamine levels ≤ 
287.5µmol/l [13]. Long – term good glycaemic control was 
Alfred Azenabor et al.,  
respectively. The number and proportion of the males to 
females in this study is 36 (23.8%): 114 (76.2%). The 
proportion of females differed significantly from the males (p 
= 0.000). A total number of 95 people had hypertension and 
this made up 63% of the DM subjects. A higher proportion of 
females 59% than males 41% had hypertension and this 
difference was statistically significant, p = 0.002. The 
presence of other co – morbidity and complications in 
addition to DM subjects with hypertension was noticed in 
109 (72.7%) of the study subjects; these included those with 
musculoskeletal syndrome 2 (1.33), neuropathy 6 (4%), 
retinopathy 4 (2.67%) and cardiovascular accident 2 (1.33%).    
The mean levels of IgM were significantly lower in DM 
subjects compared with controls; 0.82 ± 0.11µg/ml Vs 2.39 
µg/ml, p = 0.000. This is shown in table 1. Table 2 shows 
comparable differences in the humoral immunoglobulins of 
newly diagnosed DM (less than 5 years) and those with 
longer duration. Table 3 shows no association between 
immunoglobulins with duration of illness. An inverse 
relationship was observed between immunoglobulin G with 
fructosamine (r = - 0.356, p = 0.030) and glycosylated 
haemoglobin (r = - 0.352, p = 0.026) (see table 4). All studied 
humoral antibodies had significantly reduced IgM levels in 
DM subjects without any form of co – morbidity, when 
compared with DM + co- morbidity as well as apparently 
healthy control subjects. These results are shown in table 5.   
Immunoglobulin M (IgM) showed an inverse association with 
both systolic and diastolic blood pressures (see table 6).  
Table 1.  Levels (mean± SEM) of immunoglobulins A, G and M in 
DM and control subjects 
Immuno 
globulins 
DM 
n = 150 
Controls 
n = 75 
t values pvalues 
IgA ( µg/ml) 4.99± 0.44 6.25± 0.74 -1.452 0.150 
IgG ( µg/ml) 11.52± 0.27 10.84± 0.45 1.257 0.212 
IgM( µg/ml) 0.82± 0.11 2.39± 0.41 -5.255 0.000* 
*Significant 
Table 2. Levels (mean ± SEM) of immunoglobulins A, G, and M in 
DM of less than 5 Years and greater than 5 years duration 
Immunoglo
bulins 
DM<5years 
n = 85 
DM >5 years 
n = 65 
T values p value 
IgA 4.76  ± 0.51 5.45  ±  0.83 -0.750 0.456 
IgG 11.33± 0.36 11.9  ±  0.39 -0.985 0.329 
IgM 0.88  ± 0.15 0.69  ± 0.12 0.829 0.410 
 
Table 3. Association of Immunoglobulins A, G, and M in DM with 
Duration of illness using Pearson correlation coefficient 
 
Table 4. Correlation of immunoglobulins A, G and M in DM with 
Glycaemic control    indices 
Immuno 
globulins 
Fasting Plasma 
Glucose      r (p) 
Fructosamine 
    r (p) 
Glycosylated  
Haemoglobin  
r (p) 
IgA -0.035 (`0.789) 0.086(0.540) 0.094 (0.576) 
IgG -0.101(0.431) -0.356(0.030)* -0.352(0.02)* 
IgM 0.000 (1.000) 0.020(0.721)  0.014 (0.656) 
*Significant 
Table 5. Analysis of variance showing within group and between 
group comparison of the levels (mean ± SEM) of immunogloblulins 
A, G, and M in DM, DM + co - morbidity and control subjects. 
Immuno 
globulins 
DM 
n = 41 
DM + co 
morbidity 
 n = 109 
Controls 
n = 75 
F 
values 
p 
values 
IgA 5.17± 0.6 4.91 ± 0.6 6.09± 0.9 0.691 0.504 
IgG 11.8± 0.3 11.36± 0.4 10.9± 0.4 0.910 0.407 
IgM 0.68± 0.1 0.88± 0.2 2.70± 0.5 18.025 0.000* 
*significant 
Table 6. Association of immunoglobulins A, G, and M levels in DM 
subjects with systolic and diastolic blood pressures using Pearson’s 
correlation coefficient 
Immunoglobulins Systolic Blood  
Pressure r ( p ) 
Diastolic Blood  
Pressure r (p ) 
IgA -0.17 (0.894) 0.115 (0.379) 
IgG 0.072 (0.577) -0.107 (0.404) 
IgM -0.269 (0.034)* -0.257 (0.044)* 
*Significant 
DISCUSSION 
Any immune system faced with a potential threat, such as 
hyperglycaemia tries to respond. Some of these responses 
may have other devastating effect and could eventually lead 
to further damage.  In this study, we assessed the humoral 
immune response of Nigerians with type 2 DM, where 
immunoglobulins A, G and M levels in their peripheral blood 
were measured and compared with those of healthy 
controls.  Our results showed a significantly reduced plasma 
level of immunoglobulin M (IgM) in diabetic subjects when 
compared with healthy controls whilst no significant 
differences in the levels of immunoglobulins A, and G was 
observed between the two groups. The results obtained from 
this study somewhat agrees with other reports by Ardawi et 
al and Saleh in the pattern of immunoglobulin G expressed 
[12][13]. In the study by Saleh, the levels of all the humoral 
response antibodies (IgA, IgG and IgM) were decreased. 
Whilst imuunoglobulin G accounts for 70 – 75 % of the total 
serum immunoglobulin pool, IgM accounts for about 10% 
and IgA is the predominant immunoglobulin in sero – mucous 
secretions. It is interesting to note that evidence’ regarding 
the pattern of immunoglobulins A, G and M of DM in 
literature has been inconsistent. This could be attributed to 
the fact that serum immunoglobulin levels are dependent on 
a variety of conditions such as genetics, chronic disease and 
environmental factors. These also include ethnic back 
ground, age, and sex, history of allergies or recurrent 
infections, and geographic factors [14].  It is instructive to note 
Immunoglobulins 
Correlation coefficient 
r 
p values 
IgA 0.086 0.514 
IgG 0.179 0.161 
IgM -0.186 0.149 
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that immunoglobulin M is the first antibody formed in the 
primary immune response and is largely confined to the 
intravascular pool. This may aptly explain why it is the first 
antibody to be affected by the glucotoxic microenvironment 
created in diabetes.  The reduced immunoglobulin level is a 
consequence of a decrease in the percentage of activated 
(CD38+) B-cells found in diabetic patients which may 
contribute to the reduced humoral immune response 
observed in DM [15]. The mechanism by which antibodies 
further modulates the immune response in DM are not 
completely defined. It is postulated that IgM antibody 
together with antigens specifically enhance the immune 
response of that antigen, whereas IgG antibody suppresses 
the response. [16] 
In our report, we found no association between 
immunoglobulins A, G and M with duration of DM while poor 
glycaemic control (fructosamine and glycosylated 
haemoglobin) was inversely associated with only IgG.  An 
Immunoglobulin G is the classical gamma globulin, which is 
the   major circulating antibody. This immunoglobulin 
appears about 24-48 hours after antigenic stimulation and 
continues antigen antibody interaction already begun by 
Immunoglobulim M. This may possibly explain why it is 
majorly affected by poor glycaemic control compared with 
other immunoglobulins. It is instructive to note however that 
it is actually the IgM – containing immune complexes that are 
taken up by the fragment crystallisable (Fc) or Complement 3 
receptor on antigen presenting cells and are processed more 
efficiently when compared with IgG. Additionally, other 
studies have shown with respect to the biological activity of 
Immunoglobulin G from diabetics that certain functional 
properties of the Fc region of IgG are impaired; i. e. a 
decrease in binding of proteins and fixation of complement 
to the Fc fragment. These probably contribute to the 
increased susceptibility to infections, known to occur in 
poorly controlled diabetics. The reasons for the changes in 
the functional properties of the immunoglobulins are 
unknown. It is plausible that oxidation of amino acids by free 
radical mechanism is responsible for the damage of the 
complement binding site, leading to an alteration of 
biological activity. The glycation of nuclear acids may be the 
cause of DNA mutations and could alter its capacity for 
replication and transcription. Interaction with proteins and 
fixation of complement depend on the integrity of the region 
of the heavy chains. 
We have also shown in this study that over half of our 
patients with DM also had hypertension (63%). This is more 
common than other co – morbidities and complications 
observed. Hypertension, a cardiovascular risk factor and 
metabolic syndrome defining criterion is a commonly 
documented co – morbidity of DM in Nigerians. It is 
instructive to note that the presence of hypertension, with 
regards to systolic and diastolic blood pressure associated 
inversely with IgM, while DM subjects with other 
complications had an increased levels of IgM when compared 
with those without any complications.  
CONCLUSION 
Plasma levels of IgM immunoglobulins are lower in subjects 
with DM than in people without DM and while IgG and IgA 
are comparable in DM and healthy controls. Plasma IgG and 
IgM levels are significantly and inversely associated with 
glycaemic control indices and blood pressures respectively.  
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